Pulmonary Arterial Hypertension Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Pulmonary Arterial Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openopr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pulmonary Arterial Hypertension Market Report:
• The Pulmonary Arterial Hypertension (PAH) market size across the seven major markets (7MM) was estimated at around USD 6,971 million in 2025 and is expected to expand at a CAGR of 6.3% between 2024 and 2034.
• In November 2025, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage biopharmaceutical company focused on developing treatments for cardiopulmonary diseases such as pulmonary arterial hypertension (PAH), announced that it plans to advance IKT-001 into a global pivotal Phase 3 clinical trial for PAH. The Phase 3 study, titled IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is expected to begin in the first quarter of 2026.
• In September 2025, AllRock Bio Inc., a clinical-stage biotech company developing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A financing round co-led by Versant Ventures and Westlake BioPartners. The funding will support the advancement of its lead candidate, ROC-101-an oral, first-in-class pan-rho-associated protein kinase (ROCK) inhibitor exclusively licensed from Sanofi-into Phase 2 clinical trials. ROC-101 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), both life-threatening conditions with poor five-year survival rates of 57% and 38%. By targeting inflammatory, proliferative, and fibrotic remodeling driven by both ROCK1 and ROCK2, ROC-101 holds promise to meet a major unmet need in these patient populations.
• In August 2025, Cereno Scientific's lead candidate, CS1, has been granted FDA Fast Track designation for pulmonary arterial hypertension, acknowledging its promise as a novel and potentially disease-modifying therapy for this rare and severe condition.
• In August 2025, VASTHERA Co., Ltd. announced FDA clearance of its Investigational New Drug (IND) application to begin a Phase 1 trial for VTB-10, a novel candidate for pulmonary arterial hypertension (PAH). Developed via the company's proprietary RedoxizymeTM platform, VTB-10 is a first-in-class small molecule enzyme (Chemzyme) designed to mimic the function of peroxiredoxin (PRX), which is deficient in PAH lesions. Preclinical data showed that VTB-10 not only reversed abnormal vascular remodeling but also restored healthy endothelial function, offering a dual mechanism of action that sets it apart from current treatment options.
• According to DelveInsight's estimates, Germany held the largest Pulmonary Arterial Hypertension (PAH) market in EU4 and the UK, valued at approximately USD 80 million in 2024, followed by France at USD 70 million, while Spain recorded the smallest PAH treatment market size at USD 45 million in the same year.
• Several therapies are anticipated to be launched during the forecast period (2025-2034) for Pulmonary Arterial Hypertension treatment, including ralinepag (United Therapeutics), RT234 (vardenafil inhalation powder) (Respira Therapeutics), Seralutinib (GB002) (Gossamer Bio), YUTREPIA (treprostinil) (Liquidia Technologies), and L606 (liposomal treprostinil) (Pharmosa Biopharm/Liquidia).
• According to DelveInsight's estimates, the total prevalence of Pulmonary Arterial Hypertension (PAH) in the 7MM was approximately 112,700 cases in 2024, with numbers projected to rise by 2034.
• The United States holds the largest proportion of diagnosed prevalent PAH cases among the 7MM, comprising roughly 45% of the total patient population.
• In 2024, Japan recorded the second-highest number of diagnosed PAH cases among the 7MM, with approximately 23,000 cases reported.
• In 2024, EU4 and the UK reported around 26,000 treated PAH cases, with figures expected to rise by 2034.
• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that females are more affected with Pulmonary Arterial Hypertension than males
• The Pulmonary Arterial Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

Pulmonary Arterial Hypertension Overview
When measured by right heart catheterization, pulmonary hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during activity. PH has been classified into five groups by the World Health Organization (WHO) on the basis of shared pathophysiology, clinical presentation, and available treatments.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Arterial Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Arterial Hypertension Epidemiology Segmentation:
The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Pulmonary Arterial Hypertension
• Prevalent Cases of Pulmonary Arterial Hypertension by severity
• Gender-specific Prevalence of Pulmonary Arterial Hypertension
• Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openopr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Arterial Hypertension Therapies and Key Companies
• AV-101: Aerovate Therapeutics
• LTP001: Novartis
• KER-012: Keros Therapeutics
• TPN171H: Vigonvita Life Sciences
• Treprostinil Palmitil: Insmed Incorporated
• Satralizumab (Genetical Recombination): Chugai Pharmaceutical
• Sotatercept: Merck Sharp & Dohme
• Macitentan: Janssen Pharmaceutical
• ACT-293987: Actelion
• GB002 (seralutinib): Gossamer Bio
• Parenteral Treprostinil: Lung Biotechnology PBC
• Ralinepag: United Therapeutics
• Selonsertib: Gilead Sciences
• Sotatercept: Acceleron Pharma
• ubenimex: Eiger BioPharmaceuticals
• Olaparib: AstraZeneca

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=openopr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Arterial Hypertension Market Strengths
• Better understanding of disease pathophysiology and genetics has improved diagnosis and treatment, reducing mortality
• There have been significant developments in the treatment regime leading to the approval of novel therapies and more defined treatment guidelines

Pulmonary Arterial Hypertension Market Opportunities
• Further research on diagnostic and prognostic blood biomarkers in asymptomatic or specific at-risk populations to improve diagnosis and develop novel treatment options
• The increasing prevalence of PAH, along with government support for the development of orphan drugs, provide companies with an excellent opportunity to invest in the PAH market

Scope of the Pulmonary Arterial Hypertension Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Arterial Hypertension Unmet Needs, KOL's views, Analyst's views, Pulmonary Arterial Hypertension Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.